This article is from the source 'guardian' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at http://www.theguardian.com/business/2014/may/12/pfizer-defends-research-record-takeover-astrazeneca
The article has changed 5 times. There is an RSS feed of changes available.
| Version 0 | Version 1 |
|---|---|
| Pfizer defends research record in vital week for AstraZeneca takeover | |
| (about 1 hour later) | |
| Pfizer's head of research and development (R&D) has defended the US company's record on drug creation and rejected claims that AstraZeneca's programme of new treatments would suffer if Pfizer were to buy the UK pharmaceutical company. | Pfizer's head of research and development (R&D) has defended the US company's record on drug creation and rejected claims that AstraZeneca's programme of new treatments would suffer if Pfizer were to buy the UK pharmaceutical company. |
| Mikael Dolsten said Pfizer was working on about 300 projects with more than 80 in clinical development. New products reaching patients include a treatment for rheumatoid arthritis, a medicine for lung cancer and vaccines to protect children against pneumonia. | Mikael Dolsten said Pfizer was working on about 300 projects with more than 80 in clinical development. New products reaching patients include a treatment for rheumatoid arthritis, a medicine for lung cancer and vaccines to protect children against pneumonia. |
| He was speaking in corporate videos released by Pfizer as Ian Read, Pfizer's Scottish-born chief executive, flies in to the UK for his first public defence of the proposed £63bn takeover of AstraZeneca. Read will face questions from MPs on two select committees on Tuesday and Wednesday amid growing political concern over the damage the deal could do to Britain's science base. Dolsten will be questioned along with Read on Wednesday. | He was speaking in corporate videos released by Pfizer as Ian Read, Pfizer's Scottish-born chief executive, flies in to the UK for his first public defence of the proposed £63bn takeover of AstraZeneca. Read will face questions from MPs on two select committees on Tuesday and Wednesday amid growing political concern over the damage the deal could do to Britain's science base. Dolsten will be questioned along with Read on Wednesday. |
| Dolsten said: "There are a lot of exciting projects moving forward. A couple of years ago we started R&D turnaround. It was a response of R&D to Ian Read's first imperative of fixing the innovative core of the company. We have made great progress." | Dolsten said: "There are a lot of exciting projects moving forward. A couple of years ago we started R&D turnaround. It was a response of R&D to Ian Read's first imperative of fixing the innovative core of the company. We have made great progress." |
| Pfizer has made a string of acquisitions since 2000 that critics said slashed research spending to boost profits and make up for the paucity of Pfizer's own drug development programmes. Mergers in the drugs industry typically slow scientific development as research is put on hold while the companies decide what activities to cut. | Pfizer has made a string of acquisitions since 2000 that critics said slashed research spending to boost profits and make up for the paucity of Pfizer's own drug development programmes. Mergers in the drugs industry typically slow scientific development as research is put on hold while the companies decide what activities to cut. |
| AstraZeneca has tried to ward off Pfizer's unwelcome approach by emphasising the opportunities it has to bring new drugs to the market compared with Pfizer. It has warned that research will be damaged if Pfizer's takeover attempt is successful. | AstraZeneca has tried to ward off Pfizer's unwelcome approach by emphasising the opportunities it has to bring new drugs to the market compared with Pfizer. It has warned that research will be damaged if Pfizer's takeover attempt is successful. |
| The Anglo-Swedish company set out a plan for revenue growth last week in which it stressed the opportunities it had to treat cancer, diabetes and respiratory illnesses. Chief executive Pascal Soriot said Pfizer had pounced just as AstraZeneca's transformation programme was almost complete and that a takeover would set back drug development. | The Anglo-Swedish company set out a plan for revenue growth last week in which it stressed the opportunities it had to treat cancer, diabetes and respiratory illnesses. Chief executive Pascal Soriot said Pfizer had pounced just as AstraZeneca's transformation programme was almost complete and that a takeover would set back drug development. |
| AstraZeneca said on Monday that its brodalumab treatment for psoriasis, developed in partnership with Amgen, had achieved positive results in a phase III study. | AstraZeneca said on Monday that its brodalumab treatment for psoriasis, developed in partnership with Amgen, had achieved positive results in a phase III study. |
| Dolsten said Pfizer wanted to buy AstraZeneca to develop more drugs and capitalise on the UK company's presence in the "golden triangle" of London, Oxford and Cambridge, where AstraZeneca is building a research centre. | Dolsten said Pfizer wanted to buy AstraZeneca to develop more drugs and capitalise on the UK company's presence in the "golden triangle" of London, Oxford and Cambridge, where AstraZeneca is building a research centre. |
| "Pfizer has a legacy of being able to bring together cultures from different companies and add experiences from talents, from products and science, and move fast to make a new company," Dolsten said. | "Pfizer has a legacy of being able to bring together cultures from different companies and add experiences from talents, from products and science, and move fast to make a new company," Dolsten said. |
| His comments follow video statements by Read at the weekend in which he claimed a deal would be a "win-win" for all concerned. Read has tried to play down Pfizer's reputation as a slasher of costs and to present the company as an enthusiastic investor in new treatments. | His comments follow video statements by Read at the weekend in which he claimed a deal would be a "win-win" for all concerned. Read has tried to play down Pfizer's reputation as a slasher of costs and to present the company as an enthusiastic investor in new treatments. |
| Labour has called for a public interest test for the deal while Lord Sainsbury, the former science minister, has said Pfizer's bid should be blocked. | Labour has called for a public interest test for the deal while Lord Sainsbury, the former science minister, has said Pfizer's bid should be blocked. |
| With politicians and scientists increasingly questioning the proposed deal, Pfizer has sought to dispel accusations that it will cut thousands of highly skilled jobs and damage the government's aim of making Britain a centre for scientific research. | With politicians and scientists increasingly questioning the proposed deal, Pfizer has sought to dispel accusations that it will cut thousands of highly skilled jobs and damage the government's aim of making Britain a centre for scientific research. |
| Read wrote to David Cameron last week pledging to complete the Cambridge R&D centre, employ at least 20% of the combined company's R&D workforce in the UK for five years, and locate some manufacturing in Britain. | Read wrote to David Cameron last week pledging to complete the Cambridge R&D centre, employ at least 20% of the combined company's R&D workforce in the UK for five years, and locate some manufacturing in Britain. |
| But Andrew Miller, the Labour chairman of the science and technology select committee, has called for guarantees to last at least 10 years to reflect the time needed to develop new drugs. | But Andrew Miller, the Labour chairman of the science and technology select committee, has called for guarantees to last at least 10 years to reflect the time needed to develop new drugs. |
| AstraZeneca has twice rebuffed approaches from its US rival. Pfizer's second approach offered £50 a share, mainly in Pfizer's shares, but the company is expected to come back with a new bid this week with a bigger cash element. | AstraZeneca has twice rebuffed approaches from its US rival. Pfizer's second approach offered £50 a share, mainly in Pfizer's shares, but the company is expected to come back with a new bid this week with a bigger cash element. |